Mimio Health

Mimio Health is a groundbreaking nutraceutical startup at the forefront of harnessing the power of clinically-validated biomimetic cell care. With the slogan "Harness your biology with clinically-validated biomimetic cell care. Nature designed. Mimio delivered.", the company is dedicated to the research and production of the world's first fasting mimetic supplement. Founded in 2020 and based in the United States, Mimio Health has garnered significant attention in the biotechnology, health care, and pharmaceutical industries.

Mimio Health's core focus lies in leveraging extensive research on human fasting to develop a novel approach. Their patent-pending fasting mimetic formulation aims to replicate the cellular health benefits and lifespan-promoting effects of fasting without the need to fast. By utilizing a rigorously selected combination of bioactive human metabolites, Mimio Health's supplement triggers a conserved metabolic program for cellular health and regeneration, emulating the body’s natural response to fasting.

The promising implications of their work are underlined by compelling results. Their fasting mimetic has demonstrated the potential to extend the lifespan of model organisms by 96% and exhibits potent anti-inflammatory and antioxidant effects in human cells. These effects could play a pivotal role in combatting age-associated chronic inflammation and cellular damage, ultimately offering customers the opportunity to live longer, healthier lives.

Recently, the company secured a Seed Round investment on 01 March 2023 from prominent investors including SOSV, Better Ventures, indiebio, and Whatif Ventures, indicative of strong support and confidence in Mimio Health's innovative approach and potential for significant impact within the health and wellness sphere.